关于在药物研发和监管中使用真实世界数据（RWD）和真实世界证据（RWE）的现状报告。
Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.
机构信息
Clinical Pharmacology, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
ARJUNA Therapeutics, C/ XESTA №78-A2, PARQUE EMPRESARIAL NOVO MILLADOIRO - 15895 MILLADOIRO, A CORUÑA, Spain.
出版信息
Br J Clin Pharmacol. 2019 Sep;85(9):1874-1877. doi: 10.1111/bcp.14026. Epub 2019 Jul 10.
Abstract
Radically expanding use of real-world data (RWD) and real-world evidence (RWE) holds the potential to substantially impact drug development, pharmaceutical regulation, and payment within health care systems. Central to this is the reconfiguration of data gathering and transformation of data to information, which can be used as evidence for decision making. We discuss applications of this paradigm in the light of recent developments in both the United States and Europe on RWD and RWE.
摘要
真实世界数据（RWD）和真实世界证据（RWE）的广泛应用具有极大潜力，可能会对药物研发、药品监管和医疗保健系统内的支付方式产生重大影响。这一过程的核心是重新配置数据收集并将数据转化为信息，这些信息可用作决策证据。我们根据美国和欧洲最近在 RWD 和 RWE 方面的发展情况，讨论了这一模式的应用。
相似文献
1
Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.
Br J Clin Pharmacol. 2019 Sep;85(9):1874-1877. doi: 10.1111/bcp.14026. Epub 2019 Jul 10.
2
Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
Clin Pharmacol Ther. 2022 Jan;111(1):310-320. doi: 10.1002/cpt.2462. Epub 2021 Nov 16.
3
Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1213-1218. doi: 10.1002/pds.4962. Epub 2020 Jan 30.
4
The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.
J Diabetes Sci Technol. 2020 Mar;14(2):345-349. doi: 10.1177/1932296819832661. Epub 2019 Mar 12.
5
Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union.
Bioengineering (Basel). 2024 Aug 2;11(8):784. doi: 10.3390/bioengineering11080784.
6
Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Clin Pharmacol Ther. 2023 Oct;114(4):751-767. doi: 10.1002/cpt.2988. Epub 2023 Jul 29.
7
Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Drugs Real World Outcomes. 2021 Dec;8(4):459-480. doi: 10.1007/s40801-021-00266-3. Epub 2021 Jun 19.
8
Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Int J Technol Assess Health Care. 2020 Oct;36(5):474-480. doi: 10.1017/S0266462320000628. Epub 2020 Sep 15.
9
How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
Clin Transl Sci. 2022 Jan;15(1):43-54. doi: 10.1111/cts.13129. Epub 2021 Nov 15.
10
Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation.
Ther Innov Regul Sci. 2021 Jan;55(1):228-238. doi: 10.1007/s43441-020-00208-1. Epub 2020 Aug 28.
引用本文的文献
1
Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases.
Br J Clin Pharmacol. 2025 Apr;91(4):1084-1087. doi: 10.1002/bcp.70013. Epub 2025 Feb 16.
2
Expanding the use of real-world data through the development of user-friendly tools to support drug development: Example of an organ impairment dashboard.
Pharmacol Res Perspect. 2024 Aug;12(4):e1239. doi: 10.1002/prp2.1239.
3
Psychostimulants and social behaviors.
Front Pharmacol. 2024 Apr 25;15:1364630. doi: 10.3389/fphar.2024.1364630. eCollection 2024.
4
Next-generation study databases require FAIR, EHR-integrated, and scalable Electronic Data Capture for medical documentation and decision support.
NPJ Digit Med. 2024 Jan 12;7(1):10. doi: 10.1038/s41746-023-00994-6.
5
Innovative thinking of clinical investigation for rare disease drug development.
Orphanet J Rare Dis. 2023 Sep 22;18(1):299. doi: 10.1186/s13023-023-02909-w.
6
A Road Map for Peer Review of Real-World Evidence Studies on Safety and Effectiveness of Treatments.
Diabetes Care. 2023 Aug 1;46(8):1448-1454. doi: 10.2337/dc22-2037.
7
Evaluation of reporting quality of cohort studies using real-world data based on RECORD: systematic review.
BMC Med Res Methodol. 2023 Jun 29;23(1):152. doi: 10.1186/s12874-023-01960-2.
8
Harnessing Real-World Evidence to Advance Cancer Research.
Curr Oncol. 2023 Feb 2;30(2):1844-1859. doi: 10.3390/curroncol30020143.
9
Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study.
Front Pharmacol. 2022 Sep 30;13:940010. doi: 10.3389/fphar.2022.940010. eCollection 2022.
10
RWD-Cockpit: Application for Quality Assessment of Real-world Data.
JMIR Form Res. 2022 Oct 18;6(10):e29920. doi: 10.2196/29920.
本文引用的文献
1
Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure.
Drug Saf. 2019 Jul;42(7):897-906. doi: 10.1007/s40264-019-00798-2.
2
Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?
Clin Pharmacol Ther. 2019 Apr;105(4):912-922. doi: 10.1002/cpt.1226. Epub 2018 Oct 14.
3
Accelerated approval of medicines: fit for purpose?
Nat Rev Drug Discov. 2018 Jun;17(6):379-380. doi: 10.1038/nrd.2017.245. Epub 2018 Jan 5.
4
When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Clin Pharmacol Ther. 2017 Dec;102(6):924-933. doi: 10.1002/cpt.857. Epub 2017 Sep 25.
5
Improving therapeutic effectiveness and safety through big healthcare data.
Clin Pharmacol Ther. 2016 Mar;99(3):262-5. doi: 10.1002/cpt.316. Epub 2016 Jan 17.
6
Obtaining real-world evidence: the Salford Lung Study.
Thorax. 2014 Dec;69(12):1152-4. doi: 10.1136/thoraxjnl-2014-205259. Epub 2014 Mar 6.
7
Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.
Am J Gastroenterol. 2012 Apr;107(4):620-6. doi: 10.1038/ajg.2011.483. Epub 2012 Jan 31.
8
Dopamine agonist use and the risk of heart failure.
Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):34-41. doi: 10.1002/pds.2267. Epub 2011 Nov 23.
9
Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
N Engl J Med. 2009 Sep 10;361(11):1041-3. doi: 10.1056/NEJMp0906248.
10
The British Society for Rheumatology biologics register.
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv42-3. doi: 10.1136/ard.2005.042499.
Zotero 插件